American Assets Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-1,500
Closed -$276K 163
2021
Q2
$276K Hold
1,500
0.04% 130
2021
Q1
$229K Hold
1,500
0.03% 147
2020
Q4
$234K Buy
+1,500
New +$193K 0.04% 124
2020
Q2
Sell
-5,000
Closed -$449K 171
2020
Q1
$449K Buy
5,000
+1,500
+43% +$147K 0.1% 149
2019
Q4
$379K Hold
3,500
0.06% 164
2019
Q3
$343K Hold
3,500
0.06% 163
2019
Q2
$458K Hold
3,500
0.07% 158
2019
Q1
$466K Hold
3,500
0.08% 159
2018
Q4
$341K Hold
3,500
0.06% 162
2018
Q3
$484K Hold
3,500
0.08% 160
2018
Q2
$426K Buy
3,500
+1,000
+40% +$117K 0.07% 162
2018
Q1
$279K Buy
+2,500
New +$299K 0.05% 172

Other funds holding ALXN

American Assets Investment Management's ALXN Position: Q3 2021 in Review

American Assets Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,500 shares — an estimated $276K sold.

American Assets Investment Management first reported a position in ALXN in Q1 2018 and held it in 12 quarters. The position peaked at $484K in Q3 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • American Assets Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • American Assets Investment Management sold 1,500 Alexion Pharmaceuticals shares in Q3 2021, an estimated $276K.
  • American Assets Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 12 quarters.
  • American Assets Investment Management's Alexion Pharmaceuticals position peaked at $484K in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on American Assets Investment Management's 13F filing for Q3 2021, filed 21 Oct 2021.